Summit Notebook

Exclusive outtakes from industry leaders

Welcome to the 2009 Reuters Health Summit

November 9, 2009

 

 

 

Pharmaceutical companies are striking mega deals, diversifying and cutting costs to gird for the storm of patent expirations. There are signs that the industry is becoming more productive in its research labs after an extended dry patch. But investors are not convinced they are on the path to sustained profits: pharmaceutical stocks overall have underperformed the broader market in 2009, and trade in general at low premiums. 
 
Indeed, Wall Street skepticism persists in many corners of healthcare. The uncertainty over the outcome of U.S. health reform efforts has brought a cloud over the sector, none more so than for health insurers, which are at rock-bottom valuations. The weak economy weighs on medical technology companies, as hospital keep tight reins on budgets and people avoid elective procedures.
 
Some of the world’s most prominent CEOs and top executives from leading health care companies and organizations will discuss these and related issues at the Reuters Health Summit, which will generate exclusive interviews and key insights from our team of reporters as well as online video and blog postings, which will be immediately available only to Thomson Reuters clients during the Summit.

Comments

Fortunately, Government has dedicded for us that healthcare will not mean removal of our ‘free will’ altogether. The rock bottom values in healthcare and insurance companies are meerly a reflection of empty pockets of investors, while the insurance companies make greater profits than ever. Soon after the memory of the grand debate falls silent, Happy Day’s will be heard again all over Insurance heaven. Doctors and Healthcare providers must wonder how they will keep keep rolling in their billions while class who pays them eats from the public trough and garbage cans. The insurance companies win again, and as a group must be considered a buy for everyone’s portfolio who has one remaining.

 

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
  •